Search
Ionis Pharmaceuticals Inc
IONSAdd to Watchlist
74.120USD
-0.190-0.26%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
12.10BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Ionis Pharmaceuticals Inc is 8.30, ranking 140 out of 389 in the Biotechnology & Medical Research industry. The average price target is 87.00, with a high of 110.00 and a low of 46.00.
Analyst Rating
Based on
27
analysts
Buy
Current Rating
101.468
Target Price
+36.55%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Kymera Therapeutics Inc
KYMR
23
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Ionis Pharmaceuticals Inc's expected revenue for the next quarter?
Ionis Pharmaceuticals Inc's expected revenue is 189.69M.
What is Ionis Pharmaceuticals Inc's price target?
Analysts forecast that Ionis Pharmaceuticals Inc's price target is USD 87.00, with the highest forecast at USD 110.00 and the lowest forecast at USD 46.00.
How have Ionis Pharmaceuticals IncIONS's recent earnings per share performed?
The market expectation was USD -0.56, while Ionis Pharmaceuticals IncIONS's earnings per share (EPS) for the previous quarter was USD -1.41. EPS for the next quarter is expected at USD -1.09.
What is the analyst rating for Ionis Pharmaceuticals Inc?
Based on the ratings of Ionis Pharmaceuticals Inc's stock from 27 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
